A pharmaceutical composition of Azilsartan
Azisartan tablets were prepared by adding azisartan to a gel matrix formed by aqueous sodium decanoate solution and glycerin gelatin, and combining them with fillers and microcrystalline wax, which solved the problems of drug insolubleness and uneven release. , achieving uniform release and stability of the drug, and extending the drug effect maintenance time.
Patent Information
- Application Number
- CN202310426255.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-20
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-04-20
AI Technical Summary
The existing preparation methods for azisartan tablets have problems such as insoluble drug, poor stability, uneven release and excessive blood pressure reduction, making it difficult to achieve uniform release and long-term therapeutic effects in the body.
Add azisartan to the gel matrix formed by aqueous sodium caprate solution and gelatin glycerin, disperse evenly and spray it into a material containing filler and microcrystalline wax to make granular, dry, and then add disintegrant and lubricant. Tablets are pressed to form a composition to improve solubility and stability.
It significantly improves the solubility and release rate of azisartan in the digestive fluid, achieves uniform release and stability of the drug, reduces mechanical damage to the drug, and extends the drug effect maintenance time.
Smart Images

Figure CN116421571B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines, and particularly relates to an azilsartan tablet and a preparation method thereof. Background Art
[0002] Azilsartan is an angiotensin II receptor antagonist for the treatment of hypertension. It selectively blocks the binding of angiotensin II to the AT1 receptor of vascular smooth muscle, thereby blocking the vasoconstriction effect of angiotensin II, thereby producing a hypotensive effect. Compared with angiotensin-converting enzyme inhibitors (ACEI) antihypertensive drugs, azilsartan has the advantages of stable blood pressure reduction and does not cause dry cough. The drug was launched by Japan's Takeda Pharmaceutical Company in 2012 and has significant clinical efficacy.
[0003] Azilsartan is almost insoluble in water, with a solubility of less than 9 μg / mL in water. When poorly soluble drugs are made into pharmaceutical preparations, they often require special treatment to increase their in vitro dissolution rate and ensure that the drug can reach an effective concentration in the blood to achieve the desired clinical efficacy.
[0004] Chinese invention patent CN103260605B discloses a method for preparing an azilsartan composition using solid dispersion technology. The raw material and the carrier are dissolved in methanol, and a solid dispersion powder is obtained after reduced pressure drying, and then mixed with a pharmaceutically acceptable diluent, a disintegrant, and a binder to obtain a corresponding composition. This method improves the dissolution of the drug in a pH 4.5 medium, but this method uses an organic solvent and the process is relatively cumbersome, and the risk factor of large-scale production in a workshop is high.
[0005] Chinese patent CN104523632A discloses a method for preparing azilsartan tablets by combining solid dispersion technology with a solubilizer and an adsorbent. Azilsartan is dissolved in diethylene glycol monoethyl ether and prepared by adding povidone. Since diethylene glycol monoethyl ether is a high-boiling point, it is easy to cause solvent residues in the product, which brings safety issues.
[0006] Chinese invention patent CN102895205A discloses a pharmaceutical composition of azilsartan, wherein the drug is pre-micronized (D90≤12um) and mixed with corresponding excipients, and the powder is directly tableted. Although the micronization technology can reduce the drug particle size and increase the drug dissolution rate, the micronization process may damage the crystal form and increase impurities (Lipeng Sui pointed out in J. Chin. Pharm. Sci. 2014, 23 (5), 302-305). At the same time, during the storage process of micronized raw materials, the particles are easy to agglomerate and the particle size becomes larger, resulting in an increase in the particle size difference between different batches of raw materials, thereby affecting disintegration, dissolution and bioavailability.
[0007] The above schemes all prepare azilsartan preparations by pretreating the main drug or forming a solid dispersion with other components. Although the solubility of azilsartan can be improved, the solid dispersion technology is prone to cause significant changes in the physical and chemical properties of the drug, which may lead to excessive absorption of the drug in the body, causing excessive blood pressure reduction and aggravation of adverse reactions, and the drug effect is short-lived. Simply micronizing the drug is prone to poor drug stability.
[0008] For patients with hypertension, improving the absorption rate of drugs in the body is only one aspect. Specific formulation methods are also needed to control the uniform release of drugs in order to achieve stable control of blood pressure after taking the medicine.
[0009] Therefore, there is an urgent need to find a method for preparing azilsartan tablets that can ensure uniform drug release in vivo and have excellent stability. Summary of the invention
[0010] Purpose of the invention: To provide an azilsartan pharmaceutical composition which can ensure uniform release of the drug in the body and has excellent stability.
[0011] The applicant has found that adding azilsartan to a gel matrix formed by sodium caprate aqueous solution and glycerol gelatin, uniformly dispersing the mixture, spraying the mixture into a material containing a filler and microcrystalline wax for granulation, drying, adding a disintegrant and a lubricant, and tableting can significantly improve the solubility of azilsartan in digestive fluid and achieve the goal of uniform release.
[0012] In vitro dissolution experiments using artificial gastric juice and artificial intestinal juice as media confirmed that the solubility of the tablets obtained by this scheme in digestive juice was significantly improved, and the drug release rate was uniform, basically achieving the goal of uniform release. Accelerated tests proved that the addition of an appropriate amount of microcrystalline wax can significantly improve the stability of the drug.
[0013] The principle may be: Sodium caprate, as an intestinal permeation enhancer and anionic surfactant, has strong hydrophilicity and wettability, can significantly reduce the hydrophobicity of the drug, change its solubility in digestive fluid, and form a stable gel state with glycerol gelatin in water. After fully combining with azilsartan, it can control the release rate of the drug, thereby achieving the goal of uniform release. Microcrystalline wax, as a plastic material, can reduce the damage of mechanical force to the main drug during the preparation process, thereby improving the stability of the drug.
[0014] The technical solution of the present invention is: an azilsartan composition, which contains 20% azilsartan, 6-10% sodium caprate, 3-9% glycerin gelatin (calculated as anhydrous, the same below), 40-62.5% filler, 2-9% microcrystalline wax, 6-10% cross-linked polyvinylpyrrolidone, and 0.5-2% magnesium stearate.
[0015] The glycerin gelatin of the present invention is prepared by adding water to 20% glycerin and 2% gelatin to make the mixture 100% and heating the mixture.
[0016] The filler of the present invention is selected from a lactose-microcrystalline cellulose compound and a mannitol-microcrystalline cellulose compound.
[0017] Purified water is required as a solvent in the present invention, which is removed during the process and is not included in the composition.
[0018] Preferably, the azilsartan composition of the present invention contains 20% azilsartan, 7-9% sodium caprate, 4-8% glycerin gelatin, 46.8-57.2% filler, 4-6% microcrystalline wax, 7-9% cross-linked polyvinylpyrrolidone, and 0.8-1.2% magnesium stearate.
[0019] Preferably, the azilsartan composition of the present invention contains 20% azilsartan, 8% sodium caprate, 6% glycerin gelatin, 52% filler, 5% microcrystalline wax, 8% cross-linked polyvinylpyrrolidone, and 1% magnesium stearate.
[0020] The preparation method of the azilsartan composition of the present invention comprises the following steps:
[0021] Step 1: Dissolve sodium caprate in purified water to form a 5% (w / w) sodium caprate aqueous solution, then add glycerol gelatin and stir to form a gelatinous liquid;
[0022] Step 2: Add azilsartan to the colloidal liquid obtained in the first step, and use a homogenizer to stir at high speed for 2 minutes at a speed of 10000 r / min to evenly disperse the azilsartan to obtain an emulsion;
[0023] Step 3: Add filler and microcrystalline wax into a fluidized bed granulator (manufacturer: Chongqing Yingge, model: WBG-2G), set the air inlet temperature to 60°C, air volume to 40m³ / h, atomization pressure to 1.5MPa, liquid inlet speed to 12rpm, spray the emulsion obtained in the second step into the fluidized bed granulator to obtain granules, requiring the granule moisture content to be ≤1.5%;
[0024] Step 4: Use a 1.0mm aperture sieve to size the particles;
[0025] Step 5: Add crospovidone and magnesium stearate to the granulated particles and mix them evenly using a three-dimensional motion mixer;
[0026] Step 6: Compress the granules into tablets using a 7mm shallow concave die with a tablet hardness of 40-60N. Example
[0027]
[0028] 1000 tablets were prepared according to the preparation method described in the technical solution, and the specific steps are as follows.
[0029] Step 1: Dissolve sodium caprate in purified water to form a 5% (w / w) sodium caprate aqueous solution, then add glycerol gelatin and stir to form a gelatinous liquid;
[0030] Step 2: Add azilsartan to the colloidal liquid obtained in the first step, and use a homogenizer to stir at high speed for 2 minutes at a speed of 10000 r / min to evenly disperse the azilsartan to obtain an emulsion;
[0031] Step 3: Add filler and microcrystalline wax into a fluidized bed granulator (manufacturer: Chongqing Yingge, model: WBG-2G), set the air inlet temperature to 60°C, air volume to 40m³ / h, atomization pressure to 1.5MPa, liquid inlet speed to 12rpm, spray the emulsion obtained in the second step into the fluidized bed granulator to obtain granules, requiring the granule moisture content to be ≤1.5%;
[0032] Step 4: Use a 1.0mm aperture sieve to size the particles;
[0033] Step 5: Add crospovidone and magnesium stearate to the granulated particles and mix them evenly using a three-dimensional motion mixer;
[0034] Step 6: Compress the granules into tablets using a 7mm shallow concave die with a tablet hardness of 40-60N.
[0035] Embodiment 2:
[0036]
[0037] The preparation method of 1000 tablets is as described in Example 1.
[0038] Embodiment 3:
[0039]
[0040] The preparation method of 1000 tablets is as described in Example 1.
[0041] Embodiment 4:
[0042]
[0043] The preparation method of 1000 tablets is as described in Example 1.
[0044] Embodiment 5:
[0045]
[0046] The preparation method of 1000 tablets is as described in Example 1.
[0047] Comparative Example 1: No sodium decanoate in the prescription
[0048]
[0049] 1000 tablets were prepared according to the preparation method described in the following scheme.
[0050] Step 1: Add glycerin gelatin into purified water and stir until evenly dispersed;
[0051] Step 2: adding azilsartan to the glycerin-containing gelatin liquid obtained in the first step, and using a homogenizer to stir at high speed for 2 minutes at a speed of 10000 r / min to uniformly disperse the azilsartan to form a dispersion;
[0052] Step 3: Add filler and microcrystalline wax into a fluidized bed granulator (manufacturer: Chongqing Yingge, model: WBG-2G), set the air inlet temperature to 60°C, air volume to 40m³ / h, atomization pressure to 1.5MPa, spray the dispersion obtained in the second step into the fluidized bed granulator to obtain granules, requiring the granule moisture content to be ≤1.5%;
[0053] Step 4: Use a 1.0mm aperture sieve to size the particles;
[0054] Step 5: Add crospovidone and magnesium stearate to the granulated particles and mix them evenly using a three-dimensional motion mixer;
[0055] Step 6: Compress the granules into tablets using a 7mm shallow concave die with a tablet hardness of 40-60N.
[0056] Comparative Example 2: No glycerin gelatin in the prescription
[0057]
[0058] 1000 tablets were prepared according to the preparation method described in the following scheme.
[0059] Step 1: dissolving sodium decanoate in purified water to form a 5% (w / w) sodium decanoate aqueous solution;
[0060] Step 2: adding azilsartan to the sodium decanoate aqueous solution obtained in the first step, and using a homogenizer to stir at high speed for 2 minutes at a speed of 10000 r / min to uniformly disperse azilsartan in the sodium decanoate aqueous solution to form a dispersion;
[0061] Step 3: Add filler and microcrystalline wax into a fluidized bed granulator (manufacturer: Chongqing Yingge, model: WBG-2G), set the air inlet temperature to 60°C, air volume to 40m³ / h, atomization pressure to 1.5MPa, liquid inlet speed to 12rpm, spray the dispersion obtained in the second step into the fluidized bed granulator to obtain granules, requiring the granule moisture content to be ≤1.5%;
[0062] Step 4: Use a 1.0mm aperture sieve to size the particles;
[0063] Step 5: Add crospovidone and magnesium stearate to the granulated particles and mix them evenly using a three-dimensional motion mixer;
[0064] Step 6: Compress the granules into tablets using a 7mm shallow concave die with a tablet hardness of 40-60N.
[0065] Comparative Example 3: No microcrystalline wax in the prescription
[0066]
[0067] 1000 tablets were prepared according to the preparation method described in the following scheme.
[0068] Step 1: Dissolve sodium caprate in purified water to form a 5% (w / w) sodium caprate aqueous solution, then add glycerol gelatin and stir to form a gelatinous liquid;
[0069] Step 2: Add azilsartan to the colloidal liquid obtained in the first step, and use a homogenizer to stir at high speed for 2 minutes at a speed of 10000 r / min to evenly disperse the azilsartan to obtain an emulsion;
[0070] Step 3: Add the filler into the fluidized bed granulator (manufacturer: Chongqing Yingge, model: WBG-2G), set the air inlet temperature to 60°C, air volume to 40m³ / h, atomization pressure to 1.5MPa, liquid inlet speed to 12rpm, spray the emulsion obtained in the second step into the fluidized bed granulator to obtain granules, requiring the granule moisture content to be ≤1.5%;
[0071] Step 4: Use a 1.0mm aperture sieve to size the particles;
[0072] Step 5: Add crospovidone and magnesium stearate to the granulated particles and mix them evenly using a three-dimensional motion mixer;
[0073] Step 6: Compress the granules into tablets using a 7mm shallow concave die with a tablet hardness of 40-60N.
[0074] Comparative Example 4:
[0075]
[0076] Prepare 1000 tablets according to the preparation method described in the technical solution.
[0077] Comparative Example 5:
[0078]
[0079] Prepare 1000 tablets according to the preparation method described in the technical solution.
[0080] Test Example 1: Release Study
[0081] The release rates of the products of Examples 1-5 and Comparative Examples 1-5 in artificial gastric juice and artificial intestinal juice were measured respectively, and the results are recorded in Table 1.
[0082] Instrument Name: Fully Automatic Dissolution Test System
[0083] Instrument brand: sotax
[0084] Test Method: Refer to USP dissolution test method, flow cell method, open loop.
[0085] Dissolution medium: artificial gastric juice, artificial intestinal juice.
[0086] Artificial gastric juice: Take 16.4mL of dilute hydrochloric acid, add 800mL of water and 10g of pepsin and dilute to 1000mL; the dilute hydrochloric acid is 234mL of concentrated hydrochloric acid diluted to 1000mL with water to obtain 9.5%~10.5% dilute hydrochloric acid.
[0087] Artificial intestinal fluid: Take 6.8g of potassium dihydrogen phosphate and add 500mL of water to dissolve it, and adjust the pH to 6.8 with 0.1mol / L sodium hydroxide solution; take 10g of pancreatic enzyme, add appropriate amount of water to dissolve it, and dilute it to 1000mL with water.
[0088] Sampling time: 2h, 4h, 6h, 8h, 10h (1-2h for artificial gastric juice test, 2-10h for artificial intestinal juice test).
[0089] Rotation speed: 50rpm.
[0090] Test method: HPLC chromatography.
[0091] Detection wavelength: 250nm.
[0092] Preparation of reference solution: Accurately weigh about 10 mg of azilsartan reference substance, place in a 200 mL volumetric flask, add methanol to dissolve and dilute to the scale, shake well, and use as the reference solution.
[0093] Table 1 Test results of release of products in Examples 1-5 and Comparative Examples 1-5
[0094]
[0095] Figure 1 Comparison of release rates of products in Examples 1-5 and Comparative Examples 1-5
[0096] Table 1 Data and Figure 1Description: The release behavior of the azilsartan tablets of Examples 1-5 prepared by the technical solution of the present invention in artificial gastric juice and artificial intestinal juice is basically linear, and the final release is complete; while the comparative example 1 cannot be completely released, and the release behavior of the azilsartan tablets obtained in comparative examples 2, 4, and 5 is difficult to reach a linear state, and there is a problem of incomplete release. It is explained that the addition of 6-10% sodium caprate and 3-9% glycerol gelatin in the technical solution can maintain the stable release of the drug in artificial gastric juice and artificial intestinal juice, and achieve the purpose of lasting effect.
[0097] Test Example 2: Stability Study
[0098] The products of Examples 1-5 and Comparative Examples 1-5 were packaged in aluminum-plastic packaging, with 10 aluminum-plastic panels for each sample and a packaging specification of 12 pieces / panel. They were placed in an accelerated stability test box. The test conditions were a temperature of 40°C and a humidity of 75%. Samples were taken at the end of the 1st, 2nd, 3rd and 6th month, with 2 panels sampled at each time point, and related substances were determined (the shelf life standard requires total impurities ≤ 1.5%). The results are shown in Table 2.
[0099] Table 2 Total impurities / % determination results of products of Examples 1-5 and Comparative Examples 1-5
[0100]
[0101] Data in Table 2 illustrate: In the accelerated stability test, the growth rates of related substances in the products of Examples 1-5 and Comparative Examples 1-2 prepared by the technical solution of the present invention are significantly slower than those in the products of Comparative Examples 3-5, that is, the stability of the products of Examples 1-5 and Comparative Examples 1-2 is significantly better than that of the products of Comparative Examples 3-5, indicating that the addition of microcrystalline wax in an amount range of 2-9% in the technical solution can significantly improve the stability of azilsartan tablets and reduce the adverse effects of impurities produced by drug degradation on patient health.
Claims
1. A pharmaceutical composition of Azilsartan, characterized in that The pharmaceutical composition contains 20% azilsartan, 6-10% sodium caprate, 3-9% glycerin gelatin, 40-62.5% filler, 2-9% microcrystalline wax, 6-10% cross-linked polyvinylpyrrolidone, and 0.5-2% magnesium stearate. The preparation method of the pharmaceutical composition comprises: Step 1: Dissolve sodium caprate in purified water to form a sodium caprate aqueous solution, then add glycerol gelatin and stir to form a gelatinous liquid; Step 2: adding azilsartan to the colloidal liquid obtained in the first step, and using a homogenizer to stir at high speed to evenly disperse the azilsartan to obtain an emulsion; Step 3: Add the filler and microcrystalline wax into the fluidized bed granulator, and spray the emulsion obtained in the second step into the fluidized bed granulator to obtain granules; Step 4: Use a 1.0mm aperture sieve to size the particles; Step 5: adding cross-linked polyvinylpyrrolidone and magnesium stearate to the granulated particles and mixing them evenly; Step 6: tabletting the granules.
2. The pharmaceutical composition according to claim 1, characterized in that The azilsartan composition contains 20% azilsartan, 7-9% sodium caprate, 4-8% glycerin gelatin, 46.8-57.2% filler, 4-6% microcrystalline wax, 7-9% cross-linked polyvinylpyrrolidone, and 0.8-1.2% magnesium stearate.
3. The pharmaceutical composition according to claim 1, characterized in that The azilsartan composition contains 20% azilsartan, 8% sodium caprate, 6% glycerin gelatin, 52% filler, 5% microcrystalline wax, 8% cross-linked polyvinylpyrrolidone, and 1% magnesium stearate.
4. The pharmaceutical composition according to claim 1, characterized in that Glycerol gelatin is made by adding 20% glycerol, 2% gelatin to 100% water and heating.
5. The pharmaceutical composition according to claim 1, characterized in that The filler is selected from lactose-microcrystalline cellulose compound and mannitol-microcrystalline cellulose compound.
6. The pharmaceutical composition according to claim 1, characterized in that The preparation method: Step 1: Dissolve sodium caprate in purified water to form a 5% sodium caprate aqueous solution, then add glycerol gelatin and stir to form a gelatinous liquid; Step 2: Add azilsartan to the colloidal liquid obtained in the first step, and use a homogenizer to stir at high speed for 2 minutes at a speed of 10000 r / min to evenly disperse the azilsartan to obtain an emulsion; Step 3: Add filler and microcrystalline wax into the fluidized bed granulator, set the air inlet temperature to 60°C, air volume to 40m³ / h, atomization pressure to 1.5MPa, liquid inlet speed to 12rpm, spray the emulsion obtained in the second step into the fluidized bed granulator to obtain granules, requiring the granule moisture content to be ≤1.5%; Step 4: Use a 1.0mm aperture sieve to size the particles; Step 5: Add crospovidone and magnesium stearate to the granulated particles and mix them evenly using a three-dimensional motion mixer; Step 6: Compress the granules into tablets using a 7mm shallow concave die with a tablet hardness of 40-60N.
